Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor (ER) protein. Fast Track is a process designed to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
